Department of Ophthalmology, University of Washington, Seattle, Washington, United States.
Center for Developmental Biology and Regenerative Medicine, Seattle Children's Institute, Seattle, Washington, United States.
Invest Ophthalmol Vis Sci. 2024 Apr 1;65(4):43. doi: 10.1167/iovs.65.4.43.
Complement dysregulation is a key component in the pathogenesis of age-related macular degeneration (AMD) and related diseases such as early-onset macular drusen (EOMD). Although genetic variants of complement factor H (CFH) are associated with AMD risk, the impact of CFH and factor H-like protein 1 (FHL-1) expression on local complement activity in human retinal pigment epithelium (RPE) remains unclear.
We identified a novel CFH variant in a family with EOMD and generated patient induced pluripotent stem cell (iPSC)-derived RPE cells. We assessed CFH and FHL-1 co-factor activity through C3b breakdown assays and measured complement activation by immunostaining for membrane attack complex (MAC) formation. Expression of CFH, FHL-1, local alternative pathway (AP) components, and regulators of complement activation (RCA) in EOMD RPE cells was determined by quantitative PCR, western blot, and immunostaining. Isogenic EOMD (cEOMD) RPE was generated using CRISPR/Cas9 gene editing.
The CFH variant (c.351-2A>G) resulted in loss of CFH and FHL-1 expression and significantly reduced CFH and FHL-1 protein expression (∼50%) in EOMD iPSC RPE cells. These cells exhibited increased MAC deposition upon exposure to normal human serum. Under inflammatory or oxidative stress conditions, CFH and FHL-1 expression in EOMD RPE cells paralleled that of controls, whereas RCA expression, including MAC formation inhibitors, was elevated. CRISPR/Cas9 correction restored CFH/FHL-1 expression and mitigated alternative pathway complement activity in cEOMD RPE cells.
Identification of a novel CFH variant in patients with EOMD resulting in reduced CFH and FHL-1 and increased local complement activity in EOMD iPSC RPE supports the involvement of CFH haploinsufficiency in EOMD pathogenesis.
补体失调是年龄相关性黄斑变性(AMD)和早发性黄斑玻璃膜疣(EOMD)等相关疾病发病机制的关键组成部分。虽然补体因子 H(CFH)的遗传变异与 AMD 风险相关,但 CFH 和因子 H 样蛋白 1(FHL-1)在人视网膜色素上皮(RPE)中的局部补体活性的表达仍不清楚。
我们在一个 EOMD 家族中发现了一种新型 CFH 变体,并生成了患者诱导的多能干细胞(iPSC)衍生的 RPE 细胞。我们通过 C3b 分解测定评估 CFH 和 FHL-1 辅助因子活性,并通过免疫染色测定膜攻击复合物(MAC)形成来测量补体激活。通过定量 PCR、western blot 和免疫染色测定 EOMD RPE 细胞中 CFH、FHL-1、局部替代途径(AP)成分和补体激活调节剂(RCA)的表达。使用 CRISPR/Cas9 基因编辑生成同源 EOMD(cEOMD)RPE。
CFH 变体(c.351-2A>G)导致 CFH 和 FHL-1 表达缺失,并显著降低 EOMD iPSC RPE 细胞中 CFH 和 FHL-1 蛋白表达(约 50%)。这些细胞在暴露于正常人血清时表现出 MAC 沉积增加。在炎症或氧化应激条件下,EOMD RPE 细胞中的 CFH 和 FHL-1 表达与对照细胞平行,而 RCA 表达,包括 MAC 形成抑制剂,升高。CRISPR/Cas9 校正恢复了 cEOMD RPE 细胞中的 CFH/FHL-1 表达并减轻了替代途径补体活性。
在 EOMD 患者中发现新型 CFH 变体导致 CFH 和 FHL-1 减少以及 EOMD iPSC RPE 中局部补体活性增加,支持 CFH 杂合不足参与 EOMD 发病机制。